medigraphic.com

2018, Number 4

<< Back Next >>

Rev Med MD 2018; 9.10 (4)

Oral candidosis in patients with HIV/AIDS; clinical and etiological spectrum

Araiza J, Magallón-Zazueta L, Contreras-García S, Tirado-Sánchez A, Bonifaz A

Language: Spanish
References: 32
Page: 322-327
PDF size: 599.04 Kb.


ABSTRACT

Background. Patients with AIDS (acquired immune deficiency syndrome), are susceptible to acquire opportunistic infections by yeast (Candida) involving sometimes more than one species, the resistance of some species can cause failures in therapy.
Objective. To determine the frequency and clinical varieties of oral candidiasis in patients with AIDS and the Candida species involved.
Material and Methods. Analytical cross-sectional study in hospitalized patients with HIV/AIDS without previous ART (antiretroviral treatment) or cases of abandonment of the same, with clinical diagnosis of oral candidiasis. The species related to the condition was investigated with microbiological techniques, as well as with clinical evaluation of the oral candidiasis variety.
Results. We studied 65 patients, 59 men and 6 women. All in stage AIDS C3, the percentage without ART was 68%, the remaining 32% abandoned antiretroviral therapy. The most frequent clinical variety was acute pseudomembranous (90%). A total of 58 strains were found: C. albicans 71%, C. glabrata 10%, C. krusei 9%, C. dubliniensis 9% and C. kefyr 1%. The proportion of mixed candidiasis was 17%. Candida no-albicans presents higher frequency of resistance phenotypes and dose-dependent response.
Conclusions. Identifying the etiology of oral candidiasis and clinical evaluation allows to choose an adequate therapeutic scheme.


REFERENCES

  1. 1.Vázquez-González D, Per usquía-Or tiz AM, Hundeiker M, Bonifaz A. Opportunistic yeast infections: candidiasis, cryptococcosis, trichosporonosis and geotrichosis. Dtsch Dermatol Ges. 2013;11(5):381-93.

  2. Odds C, Bernaerts R. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol. 1994; 32(8):1923–9.

  3. Romero G, Araiza J, Hernández M, Cerón M, Hernández V, Ponce R, et al. Candidosis mixtas en aislamientos clínicos de pacientes procedentes del hospital general de México Dr. Eduardo Liceaga; identificación e importancia. Dermatologia Rev Mex. 2014; 58(3):239–246.

  4. Santos J, Piva E, Vilela S, Jorge A, Junqueira J. Mixed biofilms formed by C. albicans and non-albicans species: a study of microbial interactions. Braz Oral Res. 2016; 30(1):1–8.

  5. Nucci M, Marr K. Emerging Fungal diseases. Clin Infect Dis. 2005; 41(4), 521-526.

  6. Sanguinetti M, Posteraro B, Lass-Flörl C. Antifungal drug resistance among Candida species: Mechanisms and clinical impact. Mycoses. 2015; 58(2):1–13.

  7. Patton LL. Oral lesions associated with human immunodeficiency virus disease. Dent Clin North Am. 2013; 57:673-98.

  8. Hazen K. New and emerging yeast pathogens. Clin Microbiol Rev. 1995; 8(4): 462- 478.

  9. Hube B, Naglik J. Candida albicans proteinases: resolving the mystery of a gene family. Microbiology 2001; (147):1997- 2005.

  10. Ramesh N, et al. Virulence Factors and Anti-Fungal Sensitivity Pattern of Candida sp. isolated from HIV and TB patients. Indian J Microbiol. 2011; 51(3):273-8.

  11. 11.Castrillón L, Palma A, Desgarennes C. Factores de virulencia en Candida spp. Dermatología Rev Mex 2005; 49:12-27.

  12. 12.Rautemaa R, Ramage G. Oral candidosis--clinical challenges of a biofilm disease. Crit Rev Microbiol. 2011 Nov; 37(4):328-36.

  13. 13.Fernández J, Diz P, Otero X, Limeres J, De La Fuente J, Ocampo A. Valor predictivo de la candidiasis oral como marcador de evolución a SIDA. Med Oral Patol Oral Cir Oral. 2005; 10(1):32–40.

  14. Castro L, Álvarez M, Martínez E. Pseudomembranous Candidiasis in HIV/AIDS Patients in Cali, Colombia. Mycopathologia. 2013; 175(1-2):91-8.

  15. 15.Patton L, Phelan J, Ramos F, Nittayananta W, Shiboski C, Mbuguye T. Prevalence and classification of HIV-associated oral lesions. Oral Dis. 2002; 8(2):98- 109.

  16. 16.Petruzzi M, Gonçalves F, Gonçalves K, Z. de Figueiredo M. Epidemiological characteristics and HIV-related oral lesions observed in patients from a Southern Brazilian city. Rev Odonto Cienc 2012; 27(2):115-120.

  17. 17.Hamza O, Matee N, Moshi J, Simon E, Mugusi F, Mikx F, Helderman W, Rijs A, Verweij E. Species distribution and in Vitro antifungal susceptibility of oral yeasts isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BioMed Central Microbiology. 2008; 8(6): 135-143.

  18. 18.Gasparin A, Ferreira F, Danesi C, Mendoza-Sssi R, Silveira J, Martínez B, Zhang L, Juraci A. Prevalence of oral lesions in persons with HIV and associated factors in a southern Brazilian city Cad. Saúde Pública. 2009; 25(6):1307-1315.

  19. 19.Epidemiología / Registro Nacional de Casos de VIH y SIDA, Centro Nacional para la Prevención y el Control del VIH y el sida https://www.gob.mx/censida/documentos/epidemi ologia-registro-nacional-de-casos-de-sida

  20. 20.González A, Tobón A. Infecciones micóticas oportunistas en pacientes con VIH/SIDA. Infectio. 2006; 10(4): 279–288.

  21. 21.López S, Torrecilla A, Horta A, Andrade J, Bologna R. La candidosis oral como marcador clínico de falla a la terapia antirretroviral altamente efectiva en pacientes infectados con VIH/SIDA. Infectio. 2014;18 (2):45-49.

  22. 22.Noda A, Vidal L, Pérez J, Cañete R. Interpretación clínica del conteo de linfocitos T CD4 positivos en la infección por VIH. Rev Cubana Med. 2013; 52(2):118- 127.

  23. 23.Bodhade A, Ganvir S, Hazarey V. Oral manifestations of HIV infection and their correlation with CD4 count. Journal of Oral Science. 2011; 53(2):203-2011.

  24. 24.Campo J, Del Romero J, Castilla J, García S, Rodríguez C, Bascones A. Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count ans CD4 lymphocyte percentage in HIVinfected patients. J Oral Pathol Med. 2002; 31:5-10.

  25. 25.Harris J, Herrera A. Candidiasis oral en pacientes VIH/SIDA asociada a niveles de linfocitos T CD4 y terapia antirretroviral. Rev Cubana Estomatol. 2016;52(1).

  26. 26.Garzón C, Gutiérrez L, Salazar C, Barrientos S, Romero C. Especies de Candida en relación con el conteo de CD4 en pacientes con VIH-SIDA. Univ Odontol. 2008;

  27. 27(59):29-33. 27.Coleman D, Rinaldi M, Haynes K, Rex J, Summerbell R, Anaissie E, Sullivan D. Importance of Candida species other than Candida albicans as opportunistic pathogens. Med Mycol. 1998; 36(1):156-165.

  28. 28.Dilek S, Gonca E, Zayre E. The antifungal susceptibilities of oral Candida spp. Isolates from HIV-infected patients. Afr J Microbiol Res. 2010;4(6):466-470.

  29. 29.Arendrup M, Horn T, Frimodt-Moller N. In vivo pathogenicity of eigth medically relevant Candida species in an animal model. Infection. 2002; 30:286- 291.

  30. 30.Dufresne S, Marr K, Sydnor E, Staab J, Karp J, Lu K, Zhang S, Laval lée C, Perl T, Neofytos D. Epidemiology of Candida kefyr in Patients with Hematologic Malignancies. J Clin Microbiol. 2014;52(6):1830-1837.

  31. 31.Muadcheingka T, Tantivitayakul P. Distribution of Candida albicans and non-albicans Candida species in oral candidiasis patients: Correlation between cell surface hydrophobicity and biofilm forming activities. Arch Oral Biol 2014;59(3):894-901.

  32. 32.Fidel P. Candida-Host Interactions in HIV Disease: Relationships in Oropharyngeal Candidiasis. Adv Dent Res. 2006; 19:80-84.




2020     |     www.medigraphic.com